阿戈美拉汀
依西酞普兰
中止
舍曲林
临床全球印象
耐受性
氟西汀
内科学
医学
不利影响
萧条(经济学)
抗抑郁药
血清素
安慰剂
经济
替代医学
病理
宏观经济学
海马体
受体
作者
Koen Demyttenaere,E. Corruble,Anthony S. Hale,Maria-Antonia Quera-Salva,F. Picarel-Blanchot,Siegfried Kasper
出处
期刊:CNS spectrums
[Cambridge University Press]
日期:2013-03-11
卷期号:18 (3): 163-170
被引量:42
标识
DOI:10.1017/s1092852913000060
摘要
Objective A pooled-analysis on the long-term outcome in four head-to-head studies: agomelatine versus fluoxetine, sertraline, and (twice) escitalopram. Method A meta-analytic approach was used. Hamilton Depression Rating Scale (HAM-D) scores, response and remission rates, Clinical Global Impression of Improvement (CGI-I) scores, response and remission rates, and completion rates/discontinuation rates due to adverse events were analyzed. Results At the last post-baseline assessment on the 24-week treatment period, the final HAM-D-17 score was significantly lower in patients treated with agomelatine than in patients treated with selective serotonin reuptake inhibitors (SSRIs), as well in the total group of patients with severe depression (P = 0.014 and 0.040, respectively). HAM-D response rates at the end of 24 weeks were significantly higher in patients treated with agomelatine than in patients treated with SSRIs, as well in the total group of patients with severe depression (P = 0.031 and 0.048, respectively). HAM-D remission rates at the end of 24 weeks were numerically but not significantly higher in patients treated with agomelatine than in patients treated with SSRIs. Final CGI-I scores were significantly lower for agomelatine. CGI-I response as well as remission rates were numerically higher in patients treated with agomelatine, without statistical significance. The percentage of patients with at least one emergent adverse event leading to treatment discontinuation was 9.4% in patients treated with SSRIs and 6.6% in patients treated with agomelatine (P = 0.065). Conclusion The present pooled analysis shows that, from a clinical point of view, agomelatine is at least as efficacious as the investigated SSRIs with a trend to fewer discontinuations due to adverse events.
科研通智能强力驱动
Strongly Powered by AbleSci AI